Monopar Therapeutics Inc
MNPR80.950USD
+0.190+0.24%
Fechamento 11/07, 16:00（ET）Cotações atrasadas em 15 min
496.02MValor de mercado
PerdaP/L TTM
Mais detalhes de Monopar Therapeutics Inc Empresa
Monopar Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for cancer patients. The Company is building a drug candidate pipeline through in-house development as well as the licensing and acquisition of therapeutics in late preclinical and in clinical development stages. The Company has several compounds in development, which include MNPR-101-Zr, MNPR-101-RIT, Camsirubicin and MNPR-202. MNPR-101-Zr is a clinical-stage urokinase plasminogen activator receptor (uPAR)-targeted radio diagnostic imaging agent. MNPR-101-RIT is a late preclinical stage radiotherapeutic for advanced cancers. Camsirubicin is an analog of doxorubicin which has been designed to reduce the cardiotoxic side effects generated by doxorubicin while retaining effective anti-cancer activity. MNPR-202 is an early-stage analog of camsirubicin designed to potentially treat doxorubicin- and camsirubicin-resistant cancers.
Informações de Monopar Therapeutics Inc
Código da empresaMNPR
Nome da EmpresaMonopar Therapeutics Inc
Data de listagemDec 19, 2019
CEODr. Chandler D. Robinson, M.D.
Número de funcionários16
Tipo de títulosOrdinary Share
Fim do ano fiscalDec 19
Endereço1000 Skokie Blvd Ste 350
CidadeWILMETTE
Bolsa de valoresNASDAQ Capital Market Consolidated
PaísUnited States of America
Código postal60091-1146
Telefone18473880349
Sitehttps://www.monopartx.com/
Código da empresaMNPR
Data de listagemDec 19, 2019
CEODr. Chandler D. Robinson, M.D.
Executivos da empresa Monopar Therapeutics Inc
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Chandler D. Robinson, M.D.
Dr. Chandler D. Robinson, M.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
79.42K
+8.10%
Dr. Christopher M. (Chris) Starr, Ph.D.
Dr. Christopher M. (Chris) Starr, Ph.D.
Executive Chairman of the Board
Executive Chairman of the Board
16.05K
--
Ms. Lavina Talukdar
Ms. Lavina Talukdar
Independent Director
Independent Director
14.00K
--
Ms. Kim R. Tsuchimoto
Ms. Kim R. Tsuchimoto
Director
Director
11.49K
--
Mr. Arthur J. Klausner
Mr. Arthur J. Klausner
Independent Director
Independent Director
6.17K
--
Mr. Raymond William (Bill) Anderson
Mr. Raymond William (Bill) Anderson
Independent Director
Independent Director
5.37K
--
Mr. Vu Quan
Mr. Vu Quan
Chief Financial Officer, Principal Accounting Officer
Chief Financial Officer, Principal Accounting Officer
--
--
Dr. Patrice P. Rioux, M.D., Ph.D.
Dr. Patrice P. Rioux, M.D., Ph.D.
Acting Chief Medical Officer
Acting Chief Medical Officer
--
--
Mr. Andrew J. Cittadine
Mr. Andrew J. Cittadine
Chief Operating Officer
Chief Operating Officer
--
--
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Chandler D. Robinson, M.D.
Dr. Chandler D. Robinson, M.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
79.42K
+8.10%
Dr. Christopher M. (Chris) Starr, Ph.D.
Dr. Christopher M. (Chris) Starr, Ph.D.
Executive Chairman of the Board
Executive Chairman of the Board
16.05K
--
Ms. Lavina Talukdar
Ms. Lavina Talukdar
Independent Director
Independent Director
14.00K
--
Ms. Kim R. Tsuchimoto
Ms. Kim R. Tsuchimoto
Director
Director
11.49K
--
Mr. Arthur J. Klausner
Mr. Arthur J. Klausner
Independent Director
Independent Director
6.17K
--
Mr. Raymond William (Bill) Anderson
Mr. Raymond William (Bill) Anderson
Independent Director
Independent Director
5.37K
--
Detalhamento da receita
Sem dados
Sem dados
Por Empresa
Por Região
Sem dados
Distribuição de ações
Atualizado em: ter, 19 de ago
Atualizado em: ter, 19 de ago
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
Janus Henderson Investors
17.73%
Gem Pharmaceuticals LLC
9.24%
Adage Capital Management, L.P.
9.06%
RA Capital Management, LP
7.73%
AstraZeneca PLC
5.86%
Outro
50.37%
Investidores
Investidores
Proporção
Janus Henderson Investors
17.73%
Gem Pharmaceuticals LLC
9.24%
Adage Capital Management, L.P.
9.06%
RA Capital Management, LP
7.73%
AstraZeneca PLC
5.86%
Outro
50.37%
Tipos de investidores
Investidores
Proporção
Investment Advisor/Hedge Fund
20.88%
Corporation
19.21%
Hedge Fund
14.05%
Venture Capital
7.73%
Investment Advisor
5.43%
Individual Investor
4.80%
Research Firm
0.19%
Pension Fund
0.12%
Bank and Trust
0.06%
Outro
27.52%
Participação acionária institucional
Atualizado em: qua, 1 de out
Atualizado em: qua, 1 de out
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q3
99
3.34M
50.46%
+135.23K
2025Q2
76
5.07M
82.91%
-355.61K
2025Q1
72
5.03M
83.96%
+455.96K
2024Q4
54
4.84M
79.28%
+1.76M
2024Q3
40
1.90M
50.69%
+25.14K
2024Q2
43
1.96M
52.51%
+123.52K
2024Q1
46
1.91M
52.92%
+136.66K
2023Q4
44
1.88M
67.20%
+125.61K
2023Q3
42
1.87M
67.45%
+153.91K
2023Q2
38
1.84M
66.75%
+138.58K
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
Janus Henderson Investors
1.17M
17.73%
+37.96K
+3.35%
Jun 30, 2025
Gem Pharmaceuticals LLC
611.08K
9.24%
--
--
Apr 04, 2025
Adage Capital Management, L.P.
599.20K
9.06%
--
--
Jun 30, 2025
RA Capital Management, LP
511.21K
7.73%
--
--
Jun 30, 2025
AstraZeneca PLC
387.33K
5.86%
+387.33K
--
Oct 23, 2024
Tactic Pharma LLC
272.03K
4.11%
-550.23K
-66.92%
Sep 24, 2025
The Vanguard Group, Inc.
86.49K
1.31%
+31.25K
+56.59%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
183.97K
2.78%
+175.22K
+2003.49%
Jun 30, 2025
Point72 Asset Management, L.P.
104.02K
1.57%
-64.14K
-38.14%
Jun 30, 2025
Adar1 Capital Management LLC
100.97K
1.53%
+200.00
+0.20%
Jun 30, 2025
Ver Mais
ETFs Relacionados
Atualizado em: qui, 6 de nov
Atualizado em: qui, 6 de nov
Nome
Proporção
iShares Micro-Cap ETF
0.05%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
0.05%
iShares Russell 2000 Growth ETF
0.02%
Proshares Ultra Russell 2000
0.01%
Global X Russell 2000 ETF
0.01%
ProShares Hedge Replication ETF
0.01%
ProShares UltraPro Russell2000
0.01%
iShares Russell 2000 ETF
0.01%
Avantis US Small Cap Equity ETF
0%
iShares Micro-Cap ETF
Proporção0.05%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
Proporção0.05%
iShares Russell 2000 Growth ETF
Proporção0.02%
Proshares Ultra Russell 2000
Proporção0.01%
Global X Russell 2000 ETF
Proporção0.01%
ProShares Hedge Replication ETF
Proporção0.01%
ProShares UltraPro Russell2000
Proporção0.01%
iShares Russell 2000 ETF
Proporção0.01%
Avantis US Small Cap Equity ETF
Proporção0%
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Tipo
Proporção
Aug 09, 2024
Merger
5→1
Aug 09, 2024
Merger
5→1
Aug 09, 2024
Merger
5→1
Aug 09, 2024
Merger
5→1
Data
Tipo
Proporção
Aug 09, 2024
Merger
5→1
Aug 09, 2024
Merger
5→1
Aug 09, 2024
Merger
5→1
Aug 09, 2024
Merger
5→1
